Abstract
Monitoring anticoagulation when patients are receiving unfractionated heparin is essential for appropriate care to avoid bleeding or thrombotic complications. Solve it!
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gehrie E, Tormey C. Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal. Arch Pathol Lab Med. 2015;139(5):687–92.
Vandiver JW, Vondracek TG. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Hosp Pract. 2013;41(2):16–24.
Samuel S, Allison TA, Sharaf S, Yau G, Ranjbar G, Mckaig N, Nguyen A, Escobar M, Choi HA. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. J Clin Pharm Ther. 2016;41(5):499–502.
Gosselin RC, Douxfils J. Ecarin-based coagulation testing. Am J Hematol. 2020;95:863–9.
Saraçoğlu A, Ayşen Yarat A, Tetik S. The role of viscoelastic tests in trauma: “TEG and ROTEM”. J Pharmacol Med Chem. 2017;1(1):1–5.
Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran extilate therapy. Am J Clin Pathol. 2012;137(4):572–4.
Ikeda K, Tachibana H. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. J Arrhythm. 2016;32(1):42–50.
Jakowenko N, Nguyen S, Ruegger M, Dinh A, Salazar E, Donahue KR. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Thromb Res. 2020;196:276–80.
Maier CL, Asbury WH, Duncan A, Robbins A, Ingle A, Webb A, Stowell SR, Roback JD. Using an old test for new tricks: measuring direct oral anti-Xa drug levels by conventional heparin-calibrated anti-Xa assay. Am J Hematol. 2019;94(5):E132–4.
Takemoto CM, Streiff MB, Shermock KM, Kraus PS, Chen J, Jani J, Kickler T. Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring. Am J Clin Pathol. 2013;139:450–6.
Vera-Aguilera J, Yousef H, Beltran-Melgarejo D, Hugh Teng T, Jan R, Mok M, et al. Clinical scenarios for discordant anti-Xa. Adv Hematol. 2016;2016:Article ID 4054806. 6 pages. https://www.hindawi.com/journals/ah/2016/4054806/. Accessed 27 Dec 2020.
Further Reading
Gehrie E, Tormey C. Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal. Arch Pathol Lab Med. 2015;139(5):687–92.
Takemoto CM, Streiff MB, Shermock KM, Kraus PS, Chen J, Jani J, Kickler T. Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring. Am J Clin Pathol. 2013;139:450–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Friedman, M.T., West, K.A., Bizargity, P., Annen, K., Gur, H.D., Hilbert, T. (2023). The X Files. In: Immunohematology, Transfusion Medicine, Hemostasis, and Cellular Therapy. Springer, Cham. https://doi.org/10.1007/978-3-031-14638-1_73
Download citation
DOI: https://doi.org/10.1007/978-3-031-14638-1_73
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14637-4
Online ISBN: 978-3-031-14638-1
eBook Packages: MedicineMedicine (R0)